Nigerooligosaccharides augments mitogen-induced proliferation and suppresses activation-induced apoptosis of human peripheral blood mononuclear cells.
Nigerooligosaccharides (NOS), a mixture of nigerose and nigerosylmaltooligosaccharides, consists of immunopotentiating oligosaccharides found in foodstuffs. We have previously reported that activation of peripheral blood mononuclear cells (PBMC) in response to concanavalin A (Con A) or a streptococcal preparation of OK-432 is augmented in healthy young adults and elderly subjects after the intake of NOS-supplemented syrup. A reappraisal of the data suggests that NOS augments proliferation but partly suppresses activation-induced apoptosis of PBMC in response to these mitogens. To confirm this hypothesis, PBMC from healthy male subjects were stimulated with Con A or OK-432 in the presence of nigerose at the concentrations at which it was detected in the blood of subjects who had ingested NOS-supplemented syrup. Cellular activation, specifically metabolic demand, viability and proliferation, was assessed from glucose consumption, by WST-1 colorimetry and by 5-bromo-2'-deoxy-uridine incorporation assay, respectively. The Con A-induced activation of PBMC in each measurement was significantly augmented by nigerose. OK-432-induced decreases in the viability of PBMC were significantly inhibited by nigerose. Stimulation of PBMC with Con A or OK-432 induced apoptosis, but nigerose suppressed such activation-induced cell death. These results indicated that nigerose activated PBMC in vitro in a manner similar to the process observed in vivo, providing further evidence for the effectiveness of consumption of NOS-supplemented syrup.
Hirose
Yoshitaka
Y
Research and Development Section, Takeda Food Products, Ltd., Itami, Japan. Hirose_Yoshitaka@takedafood.co.jp
Murosaki
Shinji
S
Yamamoto
Yoshihiro
Y
Ikematsu
Hideyuki
H
Nomoto
Kikuo
K
D000328:Adult; D000375:Aging; D017209:Apoptosis / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D003208:Concanavalin A / Q000037:antagonists & inhibitors; D004187:Disaccharides / Q000493:pharmacokinetics* / Q000494:pharmacology*; D004338:Drug Combinations; D005947:Glucose / Q000032:analysis; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D009000:Monocytes / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D009844:Oligosaccharides / Q000493:pharmacokinetics* / Q000494:pharmacology*; D010844:Picibanil / Q000037:antagonists & inhibitors; D016032:Randomized Controlled Trials as Topic
D004187:Disaccharides; D004338:Drug Combinations; D009844:Oligosaccharides; C105508:nigerosylmaltose; C014637:laminaribiose; D003208:Concanavalin A; D010844:Picibanil; D005947:Glucose